Regeneron (REGN) reported $3.55 billion in revenue for the quarter ended June 2024, representing a year-overyear increase of 12.3%. EPS of $11.56 for the same period compares to $10.24 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.38 billion, representing a surprise of +4.84%. The company delivered an EPS surprise of +9.37%, with the consensus EPS estimate being $10.57. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Regeneron Pharmaceuticals, Inc. (REGN) reported earnings per share (EPS) of $11.56, which beat the Zacks Consensus Estimate of $10.57. The company recorded an EPS of $10.24 in the year-ago period.The upside in the bottom line can be attributed to higher revenues.Total revenues increased 12% year over year to $3.54 billion, fueled by higher Dupixent, Eylea HD and Libtayo sales. Revenues also beat the Zacks Consensus Estimate of $3.38 billion. Shares are trading up in response to the better-than-expected resu ...

Regeneron (REGN) came out with quarterly earnings of $11.56 per share, beating the Zacks Consensus Estimate of $10.57 per share. This compares to earnings of $10.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.37%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $10.20 per share when it actually produced earnings of $9.55, delivering a surprise of -6.37%.Over the last four quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3 ...

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2024 Financial and Operating Results • Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023 • Second quarter 2024 Dupixent global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second quarter 2023 • Second quarter 2024 U.S. net sales for EYLEA HD and EYLEA increased 2% to $1.53 billion versus second quarter 2023, including $304 million from EYLEA HD • Second quarter 2024 Libtayo global net sal ...

Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023Second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second quarter 2023Second quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® increased 2% to $1.53 billion versus second quarter 2023, including $304 million from EYLEA HDSecond quarter 2024 Libtayo® global net sales increased 42% to $297 million versus second quarter 2023Second quarter 2024 GAAP diluted EPS increase ...

TARRYTOWN, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the winners of the 12th annual Regeneron Prize for Creative Innovation (the Regeneron Prize), an award that recognizes, celebrates and rewards outstanding talent and creativity from early-career scientists in biomedical research. Each year, Regeneron asks leading research universities across the United States to nominate their top graduate students and postdoctoral fellows, who are then invited t ...

In its upcoming report, Regeneron (REGN) is predicted by Wall Street analysts to post quarterly earnings of $10.55 per share, reflecting an increase of 3% compared to the same period last year. Revenues are forecasted to be $3.38 billion, representing a year-over-year increase of 7.1%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 1.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during th ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Regeneron (REGN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 1, 2024, might help the stock move higher if these key numbers are better than expectat ...

serggn/iStock via Getty Images Investment Overview: Regeneron Recap Illustrates High Valuation, Justified By High Potential I last covered the Watertown, Massachusetts "Big Pharma" concern Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a note for Seeking Alpha in January, titled "Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)." At that time, Regeneron shares were worth $895 per share. While making the point that by some metrics - price-to-sales, price-to-earnings, comparisons ag ...